Copyright
©The Author(s) 2021.
World J Gastroenterol. May 7, 2021; 27(17): 2039-2053
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.2039
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.2039
SF-36 scale item | Normal phosphate population, baseline, mean ± SD | Hypophosphatemia population, baseline, mean ± SD | Difference1 at baseline, mean (95%CI) | Normal phosphate population, change at week 2, mean ± SD | Hypophosphatemia population, change at week 2, mean ± SD | Difference1 at week 2, mean (95%CI) | Normal phosphate population, change at week 6, mean ± SD | Hypophosphatemia population, change at week 6, mean ± SD | Difference1 at week 6, mean (95%CI) |
General health | 50.91 ± 20.1 | 48.50 ± 26.1 | 2.4 (-14.5 to 19.4) | -0.45 ± 12.9 | 0.75 ± 12.2 | -1.2 (-9.2 to 6.8) | 3.06 ± 16.3 | 3.25 ± 15.1 | -0.2 (-10.2 to 9.8) |
Physical functioning | 78.72 ± 22.4 | 86.11 ± 21.1 | -7.4 (-21.3 to 6.6) | 2.63 ± 10.9 | -0.28 ± 6.3 | 2.9 (-1.6 to 7.4) | 3.97 ± 14.5 | -0.28 ± 4.7 | 4.2 (0.2 to 8.3) |
Role limitations due to physical problems | 47.61 ± 42.8 | 66.67 ± 40.4 | -19.1 (-45.7 to 7.6) | -4.08 ± 28.1 | -6.25 ± 18.8 | 2.2 (-10.8 to 15.1) | 11.32 ± 39.2 | 2.08 ± 16.7 | 9.2 (-3.7 to 22.1) |
Bodily pain | 65.65 ± 25.1 | 67.17 ± 27.6 | -1.5 (-19.6 to 16.5) | 0.68 ± 18.9 | 4.42 ± 12.2 | -3.7 (-12.2 to 4.7) | 3.40 ± 19.8 | 10.83 ± 19.1 | -7.4 (-20.0 to 5.2) |
Vitality | 37.98 ± 22.0 | 40.00 ± 22.4 | -2.0 (-16.7 to 12.7) | 4.05 ± 13.1 | 7.50 ± 15.9 | -3.4 (-13.8 to 6.9) | 10.89 ± 18.0 | 12.92 ± 16.0 | -2.0 (-12.7 to 8.6) |
Mental health | 71.72 ± 18.9 | 70.33 ± 16.9 | 1.4 (-9.9 to 12.6) | 3.37 ± 9.0 | 4.33 ± 5.0 | -1.0 (-4.5 to 2.6) | 4.89 ± 13.2 | 1.67 ± 11.1 | 3.2 (-4.2 to 10.7) |
Social functioning | 68.35 ± 26.3 | 68.75 ± 30.4 | -0.4 (-20.2 to 19.4) | 3.86 ± 16.7 | 7.29 ± 13.5 | -3.4 (-12.5 to 5.6) | 8.70 ± 20.7 | 7.29 ± 15.5 | 1.4 (-9.1 to 11.9) |
Role limitations due to emotional problems | 67.91 ± 41.5 | 72.22 ± 42.2 | -4.3 (-32.1 to 23.4) | -2.66 ± 34.8 | -8.33 ± 37.9 | 5.7 (-19.1 to 30.5) | 6.52 ± 38.0 | -2.78 ± 26.4 | 9.3 (-8.8 to 27.4) |
- Citation: Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. World J Gastroenterol 2021; 27(17): 2039-2053
- URL: https://www.wjgnet.com/1007-9327/full/v27/i17/2039.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i17.2039